Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CVS Indication-Based Pricing For Cancer Drugs May Roll Out Later In 2016

This article was originally published in The Pink Sheet Daily

Executive Summary

Pharmacy benefit manager CVS is considering a range of drugs and indications for the program, noting some oncology approvals in the coming months may be eligible.

You may also be interested in...



Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors

Express Scripts' plan to reimburse at levels according to value of specific indications in inflammatory diseases will create more space for new entrants with proven value.

Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017

Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.

Medicaid Spending On Accelerated Approvals ‘Outsized’ Relative To Use

A new study highlights a subset of high-cost drugs in Medicaid for which legal and policy tools may be available to manage spending growth.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel